ANO1: More Than Just Calcium-Activated Chloride Channel in Cancer

Saisai Guo, Linna Zhang and Na Li*

Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China

ANO1, a calcium-activated chloride channel (CACC), is also known as transmembrane protein 16A (TMEM16A). It plays a vital role in the occurrence, development, metastasis, proliferation, and apoptosis of various malignant tumors. This article reviews the mechanism of ANO1 involved in the replication, proliferation, invasion and apoptosis of various malignant tumors. Various molecules and stimuli control the expression of ANO1, and the regulatory mechanism of ANO1 is different in tumor cells. To explore the mechanism of ANO1 overexpression and activation of tumor cells by studying the different effects of ANO1. Current studies have shown that ANO1 expression is controlled by 11q13 gene amplification and may also exert cell-specific effects through its interconnected protein network, phosphorylation of different kinases, and signaling pathways. At the same time, ANO1 also resists tumor apoptosis and promotes tumor immune escape. ANO1 can be used as a promising biomarker for detecting certain malignant tumors. Further studies on the channels and the mechanism of protein activity of ANO1 are needed. Finally, the latest inhibitors of ANO1 are summarized, which provides the research direction for the tumor-promoting mechanism of ANO1.

Keywords: ANO1, cancer, protein network, signal pathway, tumor microenvironment, inhibitor, miRNA

INTRODUCTION

ANO1, as a calcium-activated chloride channel (CaCC), also known as transmembrane protein 16A (TMEM16A), is a voltage-sensitive calcium-activated chloride channel with ten transmembrane fragments with amino and carboxyl-terminal structure (1). It is widely expressed in many cells, including epithelial cells, airways, smooth muscle cells, vascular endothelial cells, and myocardium. ANO1 also modulates several physiological functions, such as fluid and electrolyte secretion, intestinal motility, cardiac and neuronal excitability, vascular smooth muscle contraction, and heat pain (2, 3). Abnormal circulating ANO1 is associated with susceptibility and pathogenesis of several human diseases and pathological entities, including cystic fibrosis, various cancers, hypertension, and gastrointestinal motility disorders (4–6).

ANO1 also has a crucial role in tumor occurrence, development, metastasis, proliferation, anti-apoptosis, and epigenetic regulation is often overexpressed in tumor tissues and is an experimental target for antitumor therapies. However, the biological functions of malignant tumors remain a controversial issue. The present review aims to explore the role of ANO1 in cancer pathogenesis and therapeutics and to elucidate the mechanisms underlying the relation between ANO1 and malignancy.
ANO1 AS A POTENTIAL BIOMARKER IN CANCER

Through research on Human Protein Atlas and GEPIA database, ANO1 overexpression in various malignancies tissues (Figure 1). At the same time, up-regulation of ANO1 expression is associated with a worse prognosis in many malignant tumors (Figures 2, 3). ANO1 was reported as a promising biomarker of malignant potential, stage progression, and prognosis, aiding the monitoring of certain malignancies.

The tumor growth and metastasis were observed by transplantation of nude mice and tumor cell culture in vivo and vitro. Table 1 summarizes the role of ANO1 in different tumors. ANO1 was significantly upregulated in various malignant tumors and promotes the invasion of cancer cells. ANO1 overexpression is associated with lymph node metastasis, disease grading and poor prognosis in gastric cancer, liver cancer, and colon cancer (28, 36, 40). Overexpression of ANO1 promoted the growth and invasion of lung cancer, Head and Neck squamous cell carcinoma (HNSCC), breast cancer and pancreatic cancer through the epidermal growth factor receptor (EGFR) signal pathway (11, 22, 39). Especially in breast cancer cells, ANO1 and EGFR signal transducer and activator of transcription 3 (STAT3) signaling pathways form a positive feedback path to promote the proliferation and growth of breast cancer cells. At the same time, ANO1 also activates the Ras-Raf-MEK-ERK1/2 signaling pathway (22, 28). ANO1 and EGFR-signal transducer and activator of transcription 3 (STAT3) signaling pathways form a positive feedback path to promote the proliferation and growth of breast cancer cells. ANO1 can regulate the tumor growth factor-β (TGF-β) signaling pathway to promote Esophageal squamous cell carcinoma (ESCC) proliferation, migration, and invasion (17). Silencing or inhibition of ANO1 upregulates tumor necrosis factor-α (TNF-α) expression in prostate cancer cells (27). ANO1 can promote Hepatocellular carcinoma (HCC) and Ovarian cancer metastasis by activating the phosphatidylinositol three kinase-protein kinase B (PI3K-AKT) signaling pathway (23, 41). Meanwhile, ANO1 participates in immune escape in gastrointestinal stromal tumors (42). Finally, neutralization of ANO1 activity with gene knockdown or ANO1 inhibitors has shown anti-neoplastic actions both in vivo and in vitro models of cancer (Table 1).

In summary, it shows that ANO1 is related to cancer risk and progression in the following aspects: 1) its upregulation in a variety of tumor tissues; 2) its correlation with tumor proliferation, invasion depth, lymph node metastasis, distant metastasis, and apoptosis; 3) the gene expression level of ANO1 is closely related to tumor size and differentiation; 4) its association with advanced stage and poor prognosis; 5) its interacts with various oncogenic signaling networks; 6) it regulate tumor microenvironmental tumorigenic signaling pathways.

The expression of ANO1 seems to be controlled by various molecules and stimuli. Different cells have different regulatory mechanisms and signaling pathways. ANO1 can participate in various signal pathways not only with the interaction with various proteins but also with the ion pathway that regulates the ion homeostasis of tumor cells, thereby promoting the critical functions of tumor cells. Further studies to clarify the molecular mechanism are required, for up-regulated tumors, promoting proliferation, metastasis, invasion, and avoiding apoptosis. The mechanism of ANO1’s involvement in malignant tumors will be reviewed.

THE MECHANISM OF ANO1 INVOLVED IN CANCER

Previous studies have shown that ten biological functions formed during the multi-stage development of human tumors constitute the characteristics of cancer (43). These ten characteristics include self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, Limitless replicative potential, sustained angiogenesis, tissue invasion & metastasis, genome instability and mutation, tumor-Promoting inflammation,
deregulating cellular energetics, avoiding immune destruction. The involvement of ANO1 in tumorigenesis is currently related to the following aspects (Figure 4).

ANO1 Overexpression Is Involved in the Unlimited Replication and Proliferation of Tumor Cells
ANO1 is upregulated in various tumor tissues and correlates with proliferation, invasion depth, lymph node metastasis, distant metastasis, and apoptosis. Multiple mechanisms can explain the overexpression of ANO1. ANO1 is located on human chromosome 11q13, commonly amplified in several cancers, and participates in tumorigenesis, invasion, and migration. Therefore, the most common mechanism of ANO1 overexpression in cancer amplifies the 11q13 locus (10, 44). This expansion has been described in some cancer types, including breast, gastric, esophageal, and lung carcinoma. However, it is essential to mention that 11q13 amplification resulted in a higher TMEM16A expression in human breast cancer and HNSCC than in non-11q13-amplified tumors. Meanwhile, ANO1 is sufficient to promote cell proliferation without 11q13 amplification, which shows that 11q13 gene amplification is not the only factor that promotes ANO1 overexpression (18).

ANO1 Interacts With Various Proteins to Promote Tumor Proliferation and Invasion
EGFR is overexpressed in many tumors such as HNSCC, breast cancer, and pancreatic cancer and is involved in tumorigenesis. ANO1 was also observed as a core protein in the STRING protein network pathway, which can regulate EGFR constitutive protein phosphorylation and related signal pathways, such as protein tyrosine kinase (SRC), protein kinase B (AKT), promote the proliferation of cancer cells (18, 18).
| Cancer type | Author/year | Tumor cells | ANO1 Overexpression | ANO1 Inhibition | Clinical outcome of ANO1 over expression |
|-------------|-------------|-------------|---------------------|-----------------|----------------------------------------|
| **HNSCC**   | Ayoub (7) (2010) | HEP-2, SCC-25 | +       | +     | -                                      |
|             | Duvvuri (8) (2012) | UM-SCC1 | +       | -     | -                                      |
|             | Ruiz (9) (2012) | BHY | +       | -     | -                                      |
|             | Dixit (10) (2015) | PE/CE-PJ34 | +       | -     | -                                      |
|             | Bil (11) (2015) | Te11 | +       | -     | -                                      |
|             | Reddy (12) (2016) | SCC-25, CAL-27 | +       | -     | -                                      |
|             | Wanitchakool (13) (2017) | CAL-33, BHY, CAL-133, HT-29, T84 | +       | +     | -                                      |
|             | Finegersh (14) (2017) | NOK | +       | -     | -                                      |
|             | Hermida (15) (2018) | HPV(-)patient tissue | +       | +     | +                                      |
| **ESCC**    | Shi (15) (2013) | KYSE30, KYSE510 | +       | -     | -                                      |
|             | Yu (17) (2019) | kyse30, kyse70, KYSE140, KYSE180 | +       | +     | -                                      |
| **Breast cancer** | Britschgi (18) (2013) | ZR75-1, HCC1954, MDA-MB-415 | +       | -     | +                                      |
|             | Wu (19) (2015) | Patient tissue | +       | -     | +                                      |
|             | Fujimoto (20) (2018) | YMB-1, BT-549, MD, A-MB-453 | +       | -     | -                                      |
|             | Wu (21) (2017) | MCF7, MDA-MB-453 | +       | -     | -                                      |
|             | Wang (22) (2019) | MCF7, T47d | +       | -     | -                                      |
| **Ovarian cancer** | Liu (23) (2018) | SKO13, ES2 | +       | +     | -                                      |
| **Prostate cancer** | Liu (24) (2014) | PC3, LNCaP, DU145 | +       | +     | -                                      |
|             | Cha (25) (2015) | PC3, LNCaP, RWPE-1 | +       | +     | -                                      |
|             | Seo (26) (2015) | PC3, HT29, DU145 | +       | +     | -                                      |
|             | Song (27) (2018) | PC3 | +       | +     | -                                      |
| **Colorectal cancer** | Sui (28) (2014) | SW620, HCT116, LS174t | +       | +     | -                                      |
|             | Mokutani (29) (2016) | DLD1, HCT116 | +       | +     | -                                      |
|             | Jiang (30) (2019) | Caco-2, SW620, HCT116, SW480, LoVo | +       | +     | -                                      |
|             | Park (31) (2019) | HTC116 | +       | +     | -                                      |
| **Lung cancer** | Jia (32) (2015) | NCI-H20, H1299, GLC82 | +       | +     | -                                      |

(Continued)
The interaction between ANO1 and EGFR can also increase ANO1 protein stability. At the same time, ANO1 also has a significant effect on the remodeling of EGF-induced protein phosphorylation. The study also found that the AKT and extracellular regulated protein kinases (ERK) signaling pathways are not affected by the expression of ANO1, which was further confirmed by the STRING pathway of ANO1. So, the relationship between the expression of ANO1 and EGFR in different signaling pathways is different (39). Therefore, it is crucial to understand how ANO1 regulates the EGFR signaling pathway.

Recent data in pancreatic cancer show that ANO1 is necessary to promote EGF-induced EGFR signal transduction, EGF-mediated Ca²⁺ storage depends on ANO1, and the ANO1-

45) (Figure 5). The interaction between ANO1 and EGFR can also increase ANO1 protein stability. At the same time, ANO1 also has a significant effect on the remodeling of EGF-induced protein phosphorylation. The study also found that the AKT and extracellular regulated protein kinases (ERK) signaling pathways are not affected by the expression of ANO1, which was further confirmed by the STRING pathway of ANO1. So, the relationship between the expression of ANO1 and EGFR in different signaling pathways is different (39). Therefore, it is crucial to understand how ANO1 regulates the EGFR signaling pathway.

Recent data in pancreatic cancer show that ANO1 is necessary to promote EGF-induced EGFR signal transduction, EGF-mediated Ca²⁺ storage depends on ANO1, and the ANO1-

**TABLE 1 | Continued**

| Cancer type            | Author/year | Tumor cells | ANO1 Overexpression | ANO1 Inhibition | Clinical outcome of ANO1 over expression |
|------------------------|-------------|-------------|---------------------|-----------------|-----------------------------------------|
| Glioma                 | Hu (33)     | H1299       | + + +               | - - -           | It is associated with NF-kB signaling, MAPK signaling, and ANO1 channel activities |
| Liu (34) (2014)        | U87MG       | + + +       |                     |                 | It is associated with TGF-β signaling and related to lymph node metastasis, stage and poor prognosis; |
| Lee (35) (2016)        | U251, T98g, U138 | + +         |                     |                 | It is associated with PI3K-AKT, MAPK signaling, and related with lymph node metastasis and stage; and association with poor prognosis; |
| Gastric cancer         | Liu (36) (2015) | AGS, BGC823 | + + +               | - - -           | It is associated with NF-kB signaling, MAPK signaling, and related to lymph node metastasis, stage and poor prognosis; |
| Cao (37) (2017)        | AS, MKN45, MKN28, BGC823 | + + +       |                     |                 | It is associated with PI3K-AKT, MAPK signaling, and related with lymph node metastasis and stage; and association with poor prognosis; |
| Pancreatic adenocarcinoma | Sauter (38) (2015) | BXPC3, ASPC1 | +                   |                 | It is associated with EGFR signaling and association with lymph node metastasis, stage; |
| David (39) (2019)      | ASPC1       | + +         |                     |                 | It is associated with EGFR signaling and association with lymph node metastasis, stage; |
| Hepatocellular carcinoma | Deng (40) (2016) | SMC7721     | + +                 |                 | It is associated with PI3K-AKT, MAPK signaling, and related with lymph node metastasis and stage; and association with poor prognosis; |
| Zhang (41) (2020)      | Patient tissue | + + + + + - - - - + |                     |                 | It is associated with PI3K-AKT, MAPK signaling, and related with lymph node metastasis and stage; and association with poor prognosis; |

P, proliferation; M, metastasis; I, invasion; A, apoptosis; + promotes; - inhibits.

ANO1, a calcium-activated chloride channel; AKT, Protein Kinase B; EGFR, Epidermal Growth Factor Receptor; ERK, Extracellular Regulated Protein Kinases; ESCC, Esophageal squamous cell carcinoma; HPV, Human Papilloma Virus; MAPK, Mitogen-Activated Kinase; MEK, Mitogen-Activated Extracellular Signal-Regulated Kinase; MTOR, Mechanistic Target of Rapamycin; NF-kB, Nuclear Factor Kappa-B; PI3K Phosphatidylinositol 3 Kinase; STAT3, Signal Transducer and Activator of Transcription three; TGF-a, Tumor Necrosis Factor-α TGF-a, Tumor Necrosis Factor-β, FIGO, Federation International of Gynecology and Obstetrics.

**FIGURE 4 | The involvement of ANO1 in tumorigenesis.**
mediated Ca²⁺ signaling pathway regulates EGF-induced may be involved in the proliferation of pancreatic cancer cells, and may dramatically impact the migration (46, 47). It can be seen that ANO1 provides a new entry point for treating pancreatic cancer.

In the study of breast cancer cells, EGF initiates EGFR/STAT3 signal transduction, which promotes the overexpression of ANO1, while ANO1 overexpression further activates the EGFR-STAT3 signal transduction of breast cancer cells. The positive feedback loop between ANO1 and EGFR-STAT3 promotes the proliferation and migration of breast cancer cells. Knockout of ANO1 will reduce the phosphorylation of EGFR in breast cancer cells, further inhibit the activation of AKT, SRC, and ERK, and reduce the autocrine of EGFR ligands, EGF and TGF-β, suggesting that ANO1 may increase EGFR ligands. The autocrine activates EGFR signal transduction (22). Therefore, we considered that ANO1 could activate the EGFR signaling pathway by increasing EGFR expression, phosphorylation, and EGFR ligand autocrine. More research is needed to confirm the connection between ANO1 and EGFR.

ANO1 also regulates cell morphology and volume and directly interacts with scaffold ERM protein (Ezrin/Radixin/Moesin) (48) (Figure 5). The ERM protein connects the plasma membrane with the actin cytoskeleton, affects the cell morphology of cancer cells, and regulates the movement, metastasis, and invasion of tumor cells. At the same time, ERM can be activated by many ligands as scaffold proteins to promote the signal transduction of membrane proteins, including EGFR ligands, to promote the deformation and invasion of cancer cells. Studies have found that ANO1 may interact with EGFR to recruit ERM proteins, promoting EGFR signal transduction and activation of the MAPK/AKT pathway (11).

The ANO1 inhibitor Des inhibited the activity and migration of non-small-cell lung carcinoma by decreasing the levels of Ano1, p-ERK1/2 and p-EGFR (49).

**ANO1 Activates Multiple Signaling Pathways Involved in Tumor Proliferation, Migration and Invasion**

There is ample evidence that ANO1 triggers numerous signaling pathways and stimulates many biological effects in various cell types (Figure 6). Overexpression of ANO1 promoted the growth and invasion of lung cancer cells through the EGFR-MAPK signal pathway (33). ANO1 also activates the Ras-Raf-MEK-ERK1/2 signaling pathway to promote tumor cell growth of HNSCC (8). At the same time, ANO1 can regulate the TGF-β signaling pathway to promote ESCC cells proliferation, migration, and invasion (17). Silencing or inhibition of ANO1 inhibits cell growth, induces apoptosis, and upregulates TNF-α expression in prostate cancer cells (22). Calcium ions (SOCE) that activate ANO1 and ANO1-dependent storage can enter cells and regulate EGFR ligands to promote pancreatic cancer cell migration (39). The higher the expression level of ANO1 in HCC is accompanied by higher tumor grades, lesions, metastases, and a poor prognosis (40, 41). ANO1 can promote HCC metastasis by activating EGFR phosphorylation and subsequent PI3K-AKT signaling pathway (41). In breast cancer cells, ANO1 and EGFR-STAT3 signaling pathways form a positive feedback path to promote the proliferation of breast cancer cells (22). At the same time, ANO1 mediated the PI3K-AKT-mTOR and JAK-STAT3 signaling pathways of HER2-positive breast cancer cells by regulating intracellular Cl⁻ to participate in HER2 transcription.
and promote tumor proliferation (21). Inhibit of ANO1 can inhibit PI3K-AKT signaling and inhibit the Ovarian cancer cell proliferation and invasion (23). ANO1 affects GBM cell proliferation by regulating NF-κB mediated genes. In the meantime, it is involved in cell proliferation cyclin D1, cyclin E and c-myc, and matrix metalloproteinase (MMP) 2 and MMP 9 induce GBM cell invasion and migration (34, 35). Higher expression of ANO1 was related to gastric and colorectal cancer lymph node metastasis, advanced tumor stage and poor prognosis. Knockout or pharmacological inhibition of ANO1 inhibits the proliferation and induces apoptosis of colorectal cancer cells via the Wnt/β-catenin signaling pathway (50). ANO1 is a direct target and negatively correlates with miR-9, miR-144 and miR-381 (30, 31, 37). Overexpression of miR-9 suppressed the expression of p-AKT, cyclin D1, and p-ERK. MiR-144 can inhibit colorectal cancer by inhibiting the EGFR-ERK signaling pathway targeting ANO1. Meanwhile, miR381 directly targets ANO1 to regulate the TGF-β pathway. ANO1 also has been considered an independent prognostic factor affecting the prognosis of gastric cancer patients.

ANO1 participates in various signaling pathways to promote proliferation, metastasis, and invasion. The signal pathway involved in each tumor is not unique, and one signal pathway can correspond to multiple tumor types. To this end, it would be significant to determine the ANO1 receptor and clarify its signaling pathway in tumor promotion.

Meanwhile, ion channels also participate in ANO1 regulated signaling pathways. Some scholars believe that ANO1 may regulate EGF through Ca²⁺ signaling to promote pancreatic cancer cell migration (39). Some scholars have also found that silencing the expression of ANO1 reduces the intracellular Cl⁻, thereby reducing the secretion of TGF-β and inhibiting the metastasis and invasion of gastric cancer cells (36). At the same time, in breast cancer cells, a decrease in the activity of the Cl⁻ channel can down-regulate the EGFR signaling pathway (18). The mechanism of ANO1 in each tumor is different, so that it may constitute the heterogeneity of ANO1 overexpressing cancer cells. However, further studies are needed to clarify whether specific cancer types have unique ionic states.

### Alteration of ANO1 Protein Level and Ion Channel Activity Promotes Cancer Cell Proliferation and Migration

Many studies are researching how the increase in ANO1 protein level and channel activity is involved in the proliferation and migration of malignant tumor cells. The gating characteristics of ANO1 are complex because it involves the increase in intracellular calcium ion concentration, membrane depolarization, and the interaction between extracellular chloride or transition anions and intracellular protons (11).

ANO1 contains ten putative transmembrane domains, intracellular NH2 and COOH end, and two calmodulin-binding domains (51). E702 and E705 are presumed to be Ca²⁺ binding sites, and ANO1 expresses multiple splice variants with variable sensitivity to cytoplasmic Ca²⁺. Studies have found an X-ray crystal structure (52) (a fungus with Ca²⁺ activated lipid interfering enzyme activity nhTMEM16) ANO1 subtype has 39-42% homology with mammalian ANO1 (53, 54). nhTMEM16 contains ten transmembrane subunit fragments and six residues (including glutamic acid and aspartic acid). Exploring the fungal model of ANO1 will help determine the Ca²⁺ binding site. However, the exact Ca²⁺ binding mechanism of ANO1 still needs to be further explored, even identifying the Ca²⁺ binding site and ionic conductive hole of ANO1.

For the structural study of ANO1, the current research shows two main ion phenomena: A) ANO1 is activated by voltage when Ca²⁺ is absent in tumor cells. B) After reducing the concentration of extracellular Cl⁻, the conductivity of Cl⁻ in ANO1 decreases (55).
The intracellular Ca\(^{2+}\) signaling is an essential regulator of cell proliferation, and ANO1 can control intracellular Ca\(^{2+}\) levels by regulating Ras-Raf-MEK-ERK1/2, PIK3-AKT, and DAG-IP3 receptor signals (11, 51). In many systems, the transient increase of intracellular Ca\(^{2+}\) and the continuous activation of the Ras-Raf-MEK-ERK1/2 pathway are the central links in cell proliferation (51, 56, 57). The steady-state regulation of Ca\(^{2+}\) and chloride ion conductance in ANO1 channel activity is also involved in the EGFR-induced EGFR pathway. In addition, Cephalanthine significantly inhibits cell proliferation, migration and induces apoptosis in lung adenocarcinoma cells via endogenous ANO1 currents (58). Change and regulation of Ca\(^{2+}\) concentration play an essential role in the ANO1 function of cancer cells.

At the same time, the Cl\(^{-}\) channel is the key to maintaining cell volume, so it is crucial in tumor cell migration and invasion (44, 59, 60). In cancer, related changes in intracellular water content can regulate cell volume, and the resulting morphological changes are critical to cell division, migration, invasion, and prevention of cell death (61, 62). The osmotic adjustment represents a mechanism that links ion flux to different cancer cell functions. Some reports have observed that inhibiting ANO1 can affect the size or morphology of cancer cells (7, 60, 63). Furthermore, the activation of Cl\(^{-}\) concentration in ANO1 can regulate cell proliferation, and the overexpression of cell ANO1 protein and the increase of channel activity may lead to changes in Cl\(^{-}\)-concentration. Intracellular Cl\(^{-}\) can function as a second messenger, regulating various proteins in many signaling pathways (48, 64). So far, it is still unclear whether the overexpression of ANO1 will increase or decrease the concentration of Cl\(^{-}\). Some scholars have put forward the hypothesis: If ANO1 overexpression can reduce the concentration of Cl\(^{-}\), it may be by increasing the outflow of Cl\(^{-}\) in the cell. Experiments have shown that the Cl\(^{-}\) channel associated with glioblastoma can be transported to the plasma membrane and act as an ion channel, explicitly participating in tumorigenesis (65).

Next, we determined that the homeostasis regulation of Ca\(^{2+}\) and Cl\(^{-}\) currents also has a more significant effect on ANO1 in cancer cells. Some scholars established a 12-state Markov chain model by studying the mechanism of membrane potential, Ca\(^{2+}\), and Cl\(^{-}\) on ANO1 ion channel gating (54). This model interprets the activation of ANO1 as 2 Ca\(^{2+}\) dependent on the membrane voltage, directly and continuously coupled with the external Cl\(^{-}\) dependent on the membrane potential, and transition into a voltage-dependent state. This model assumes that further experiments prove no significant change in extracellular Cl\(^{-}\) affinity for ANO1 Ca\(^{2+}\). However, experiments have also found that extracellular Cl\(^{-}\) can promote voltage-dependent activation by stabilizing the open configuration induced by Ca\(^{2+}\). The establishment of the model helped to understand the ion channel mechanism of ANO1. However, the related mechanism of ANO1 channel activity and tumor also needs to be confirmed in other models.

While most reports have confirmed the role of ANO1 overexpression in cancer cell proliferation and migration, there is insufficient information on the role of ANO1 in cell proliferation and migration, mainly due to the increase in ANO1 protein level or the increase in channel activity. Studies have found that reducing the expression level of ANO1 protein may be more critical than blocking the activity of ANO1 channels (66).

### ANO1 Induces Tumor Cells to Escape Apoptosis and Regulate the Cell Cycle

Apoptosis is a highly regulated process of cells, essential for cell growth and tissue development (67, 68). Exogenous pathways can trigger apoptosis, including extracellular, pro-apoptotic, ligand-receptor interaction, and endogenous (69). In breast cells, the expression of ANO1 increased anti-apoptotic proteins BCL2 and MCL-1, indicating that ANO1 has pro-survival and anti-apoptotic functions (18). TNF-\(\alpha\) expression was negatively correlated with ANO1 expression in prostate cancer cells. Inhibition of ANO1 can activate the TNF-\(\alpha\) signaling and induce apoptosis via caspase activation (27). ANO1 also may regulate HCC cell apoptosis through the control AKT/MAPK signaling pathway (41). ANO1 expression correlates with increased ERK 1/2 activity and less apoptotic activity in HNSCC (70). ANO1 inhibitors can cause the overexpression of miR9 to inhibit the proliferation of colorectal cancer cells and induce cell cycle arrest at the G0/G1 phase leading to cell apoptosis (31). At the same time, inhibiting ANO1 can reduce the chloride channel activity and the expression of EGFR and calmodulin dependent kinase (CAMKII), thus promoting breast cancer cell apoptosis (18). Therefore, suppression of ANO1 overexpression induces apoptosis and offers a promising new modality for the future treatment of malignant tumors.

The G1 phase arrest of the cell cycle can slow cell proliferation. Studies have found that inhibiting ANO1 can induce cell cycle G2/M phase arrest. Nevertheless, it does not affect cell cycle distribution (71). Meanwhile, changes in ANO1 expression affect proteins used explicitly for transcription or cell division. Such as cyclin A2, cyclin D1, and cyclin E. Up-regulation of cyclin-dependent kinases 1 and 2 (CDK1 and CDK2) in cancer cells can cause an increase in the expression of ANO1 (34, 52). The above data indicate that ANO1 may be involved in the cell cycle process, but it remains to be clarified how ANO1 induces tumor cell cycle arrest. Existing studies have found that the ANO1 inhibitor Caccinh-A01 may reduce the chloride current in gastric cancer cells and cause the G1 phase of the cell cycle block (72). At the same time, research on colorectal cancer found that cyclin D1 protein expression was positively correlated with ERK1/2 and ANO1.ANO1 inhibits G1 to S phase progression by down-regulating the expression of the ANO1, which is consistent with the decreased expression of cyclin D1 (28). Suppressing ANO1 expression also had significantly lower cyclin D1, leading to changes in p27\(^{Kip1}\) distribution and correlated with a cell cycle arrest phenotype in HNSCC (8, 73).

### ANO1 Is Involved in Tumor Immune Evasion

Tumor immune escape signifies that tumor cells escape recognition and attack by the immune system through various mechanisms to survive and proliferate (74). Future development of cancer immunotherapy depends on the crosstalk between cytokines produced by the tumor microenvironment and
biology. In the study of gastrointestinal stromal tumors, ANO1 gene expression was significantly negatively correlated with plasma cells and activated memory CD4+ T cells, implying that ANO1 may be involved in the functional inhibition of helper T cells (42). We consider that ANO1 may be related to the immune microenvironment of malignant tumors. These specific mechanisms also remain to be systematically investigated.

PERPECTIVES AND FUTURE DIRECTIONS OF ANO1

As a calcium-activated chloride channel, ANO1’s expression is affected by various molecular mechanisms. Current research shows that ANO1 may be involved in malignant tumors’ occurrence, development, and metastasis. Finally, novel, more effective, and safer ANO1-centered therapeutic interventions may open new horizons in oncology and provide a new cancer treatment strategy. Some compounds such as cepharanthine (58), Ani9 (36, 75), cinobufagin (76), luteolin (77), Aa3 (78), theaflavin (79), 2-aminothiophene-3-carboxamide derivatives (80), matrine (76), have been identified as inhibitors of ANO1. It has been validated in multiple in vitro and vivo tumor models (Table 2).

Simultaneously, microRNAs (miRNAs) can also directly target and inhibit ANO1 expression suppressing tumor cells. MiRNA is small non-coding RNAs with about 22 nucleotides. miRNAs play an essential regulatory role in various cancers, including gastric cancer, pancreatic cancer, and hepatocellular carcinoma. They bind to the 3’-untranslated region (3’-UTR) of target genes, resulting in irreversible inhibition of transcription or translation. Because abnormally expressed miRNA also contributes to cancer cells’ proliferation, apoptosis, and metastasis (87–89). Moreover, miRNA expression is considered a promising biomarker of cancer diagnosis, prognosis, and therapy (90).

Existing studies have found that luciferase detection shows that ANO1 is a direct target and is negatively correlated with miR132, miR144, miR381, and miR9 (Figure 7). High miR144 and miR9 directly target ANO1 to inhibit colorectal cell proliferation and migration and promote apoptosis (30, 31). miR9 overexpression inhibits ANO1 miRNA and protein expression and inhibits the expression of P-AKT, CD1, and P-ERK proteins in colorectal cancer cells (31). miR381 expression is related to gastric cancer proliferation, lymph node metastasis, advanced stage, and poor prognosis by directly targeting ANO1 to regulate the TGF-β pathway (37). MiR144 also down-regulates the expression of PTEN to activate the Ras-Raf-MEK-ERK1/2 pathway to inhibit breast cell proliferation and survival (30). Exploring the relationship between ANO1 and microRNA has broad prospects for the occurrence and development of tumors.

SUMMARY

ANO1 has recently attracted considerable attention because of its potential role in cancer chemoprevention and chemotherapy.

| ANO1 inhibitors | Tumor cells | Mechanisms | Year |
|-----------------|-------------|------------|------|
| Cepharanthine (58) | LA795, PC9 | reduced ANO1 channel activity | 2021 |
| Diethylstilbestrol (DES) (49) | | 1. reduced both ANO1 channel activity and cell viability | 2021 |
| | | 2. reduction of p-ERK1/2 and p-EGFR levels. | |
| | | 3. induced apoptosis by increasing caspase-3 activity and PARP-1 cleavage | |
| Ani9 (75, 80) | PC3, MCF7, BxPC3, DU145, LNCaP, 22RV1 | 1. reduced the protein levels | 2016 |
| | | 2. TNF-α signaling, activation of JNK and JUN | 2018 |
| | | 1. suppress ANO1 channel activities | 2020 |
| | | 2. combination of ANO1 inhibitor (9c or 3) and temozolomide (TMZ) brings about remarkable synergistic effects | |
| T18A(inh)-A01 (38, 82) | Panc-1, Mia PaCa2, Capan-1, AsPC-1, BxPC-3, HEK-293T, UM-SCC1, T24, DU145, LNCaP, 22RV1 | 1. suppress ANO1 channel activities | 2012 |
| | | 2. regulated ERK1/2 activation and cyclin D1 | 2018 |
| | | 3. TNF-α signaling, activation of JNK and JUN | |
| Arctigenin (63) | LA795 | Inhibited MAPK pathway | 2020 |
| CaCCinh-A01 (38) | Panc-1, Mia PaCa2, Capan-1, AsPC-1, BxPC-3, DU145, LNCaP, 22RV1 | TNF-α signaling, activation of JNK and JUN | 2015 |
| | | 1. suppressed phosphorylation of STAT3 | 2018 |
| | | 2. induced caspase-3 activation and PARP cleavage | |
| | | inhibited ANO1 channel activity and protein expression levels | 2017 |
| | | inhibited ANO1 channel activity | 2019 |
| | | 2. inhibited ion conduction pore | 2021 |
| Luteolin (77) | PC3 | 1. inhibited ATP-induced [Ca2+]i signals | 2021 |
| Matrine (84) | LA795 | NR | 2019 |
| benzophenanthridine alkaloids (85) | LA795 | inhibited ANO1 channel activity | 2020 |
| Avermectins (86) | LA795 | NR | 2020 |
| Aa3 (78) | A549, NCI-H460 | NR | 2020 |
| Theaflavin (79) | LA795 | block the ion conduction pore | 2021 |

NR, not reported.
ANO1 can participate in various signal pathways by interacting with a variety of proteins or by regulating the ion conduction of malignant tumor cell ion homeostasis, thereby affecting the biological behavior of malignant tumors. Moreover, ANO1 expression can constitute a vital diagnosis and therapy monitoring marker. Advances in ANO1 biology and ANO1 inhibitors may hold promise for ANO1 use as a potential cancer biomarker and therapeutic target. The development of ANO1 inhibitors is currently desirable and validated in multiple in vitro and vivo tumor models and used in clinical trials. Simultaneously, many questions remain to be answered, yet other fields need additional exploration.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

**REFERENCES**

1. Paulino C, Neldner Y, Lam AK, Kalienkova V, Brunner JD, Schenck S, et al. Structural Basis for Anion Conduction in the Calcium-Activated Chloride Channel TMEM16A. *Elife* (2017) 6:1–23. doi: 10.7554/eLife.26232
2. Schroeder BC, Cheng T, Jan YN, Jan LY. Expression Cloning of TMEM16A as a Calcium-Activated Chloride Channel Subunit. *Cell* (2008) 134:1019–29. doi: 10.1016/j.cell.2008.09.003
3. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, et al. TMEM16A, a Membrane Protein Associated With Calcium-Dependent Chloride Channel Activity. *Science* (2008) 322:590–4. doi: 10.1126/science.1163518
4. Pedemonte N, Galietta LJ. Structure and Function of TMEM16 Proteins (Anoctamins). *Physiol Rev* (2014) 94:419–59. doi: 10.1152/physrev.00039.2011
5. Oh U, Jung J. Cellular Functions of TMEM16/anoctamin. *Pflugers Arch* (2016) 468:443–53. doi: 10.1007/s00424-016-1790-0

6. Qu ZQ, Yao WC, Yao RY, Liu XP, Yu K, Hartzell C. The Ca(2+)-Activated Cl (-) Channel, ANO1 (TMEM16A), Is a Double-Edged Sword in Cell Proliferation and Tumorigenesis. *Cancer Med* (2014) 3:453–61. doi: 10.1002/cam4.232
7. Ayoub C, Wasylyk C, Li Y, Thomas E, Marisa L, Robe A, et al. ANO1 Amplification and Expression in HNSCC With a High Propensity for Future Distant Metastasis and Its Functions in HNSCC Cell Lines. *Br J Cancer* (2010) 103:715–26. doi: 10.1038/sj.bjc.6605823
8. Duvvuri U, Shiwasaki DJ, Xiao D, Bertrand C, Huang X, Edinger RS, et al. TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. *Cancer Res* (2012) 72:3270–81. doi: 10.1158/0008-5472.CAN-12-0475-T
9. Ruiz C, Martins JR, Rudin F, Schneider S, Dietsche T, Fischer CA, et al. Enhanced Expression of ANO1 in Head and Neck Squamous Cell Carcinoma Causes Cell Migration and Correlates With Poor Prognosis. *PloS One* (2012) 7:e43265. doi: 10.1371/journal.pone.0043265

**AUTHOR CONTRIBUTIONS**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**FUNDING**

This study was partially supported by China’s National Natural Science Foundation(81900198), the Dalian Science and Technology Innovation Program, and the Natural Science Foundation of Liaoning Province(2020-MS-257).
10. Dixit R, Kemp C, Kulich S, Seethala R, Chieosa S, Ling S, et al. TMEM16A/ANO1 Is Differentially Expressed in HPV-Negative Versus HPV-Positive Head and Neck Squamous Cell Carcinomas Through Promoter Methylation. Sci Rep (2015) 5:16657. doi: 10.1038/srep16657

11. Bill A, Gaither LA. The Mechanistic Role of the Calcium-Activated Chloride Channel ANO1 in Tumor Growth and Signaling. Adv Exp Med Biol (2017) 966:1–14. doi: 10.1007/978-2016_201

12. Reddy RB, Bhat AR, James BL, Govindan SV, Mathew R, Ravindra DR, et al. Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer. PloS One (2016) 11: e0147409. doi: 10.1371/journal.pone.0147409

13. Wanitchakool P, Wolf L, Koehl GE, Sirianant L, Schreiber R, Kulkarni S, et al. Regulation of Proliferation by Ano1/TMEM16A in Breast Cancer With Unknown F Unction 16A Overexpression Promotes Glioma Formation Through the Unknown F Unction. Cancer Res (2013) 112:9722–32. doi: 10.1158/1078-0432.CCR-12-3753

14. Mokutani Y, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, et al. Down-Regulation of microRNA-132 is Associated With Poor Prognosis of Colorectal Cancer. Ann Surg Oncol (2016) 23:599–608. doi: 10.1097/1073/pr-0115443

15. Shi ZZ, Shang L, Jiang YY, Hao JJ, Zhang Y, Zhang TT, et al. Consistent and Reproducible alteration of Genes at 11q13 in Relation to HPV Status With Impact on Survival in Head and Neck Cancer Patients. J Clin Med (2018) 7:1–14. doi: 10.3390/jcm7120501

16. Shi ZZ, Shang L, Jiang YY, Hao JJ, Zhang Y, Zhang TT, et al. Consistent and Reproducible alteration of Genes at 11q13 in Relation to HPV Status With Impact on Survival in Head and Neck Cancer Patients. J Clin Med (2018) 7:1–14. doi: 10.3390/jcm7120501

17. Yu Y, Cao J, Wu WB, Zhu Q, Tang Y, Zhu CX, et al. Genome-Wide Copy Number Variation Analysis Identified ANO1 as a Novel Oncogene and Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. Carcinogenesis (2019) 40:1198–208. doi: 10.1093/carcin/bgz077

18. Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, et al. Calcium-Activated Chloride Channel ANO1 Promotes Breast Cancer Progession by Activating EGFR and CAMK Signaling. Proc Natl Acad Sci U.S.A. (2013) 110: E1026–34. doi: 10.1073/pnas.1217072110

19. Wu HZ, Guan S, Sun ML, Yu ZJ, Zhao L, He M, et al. Ano1/TMEM16A Overexpression Is Associated With Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients Following Tamoxifen Treatment. PloS One (2015) 10:e0126128. doi: 10.1371/journal.pone.0126128

20. Fujimoto M, Kito H, Kajikuri J, Ohya S. Transcriptional Repression of Human Calcium-Activated Chloride Channel ANO1 in Tumor Growth and Signaling. Adv Exp Med Biol (2017) 966:1–14. doi: 10.1007/978-2016_201

21. Wang H, Yao F, Luo SY, Ma K, Liu ML, Bai LC, et al. A Mutual Activation Loop Between the Ca2+-(+) Activated Chloride Channel TMEM16A and EGFR/STAT3 Signaling Promotes Breast Cancer Tumorigenesis. Cancer Lett (2019) 455:48–59. doi: 10.1016/j.canlet.2019.04.027

22. Liu ZT, Zhang SS, Hou F, Zhang CX, Gao JJ, Wang KW. Inhibition of Ca2+-(+) Activated Chloride Channel ANO1 Suppresses Ovarian Cancer Through Inactivating P38/Akt Signaling. Int J Cancer (2019) 144:22125–26. doi: 10.1002/iarc.31887

23. Liu W, Lu M, Liu RG, Huang Y, Wang KW. Inhibition of Ca2+-(+) Activated Cl (-) Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma. Cancer Lett (2012) 326:41–51. doi: 10.1016/j.canlet.2012.07.015

24. Cha JY, Wee JW, Jung JY, Jang YW, Lee B, Hong GS, et al. Anoctamin 1 (TMEM16A) is Essential for Testosterone-Induced Prostate Hyperplasia. Proc Natl Acad Sci U.S.A. (2015) 112:9772–7. doi: 10.1073/pnas.1423827112

25. Seo Y, Ryu K, Park J, Jeon DK, Jo S, Lee HK, et al. Inhibition of ANO1/TMEM16A Chloride Channel by Ibedione and Its Cytotoxicity to Cancer Cell Lines. PloS One (2015) 10:e0133656. doi: 10.1371/journal.pone.0133656

26. Song Y, Gao J, Guan LZ, Chen XL, Gao J, Wang KW. Inhibition of ANO1/TMEM16A Induces Apoptosis in Human Prostate Carcinoma Cells by Activating TNF-Alpha Signaling. Cell Death Dis (2018) 9:703. doi: 10.1038/s41419-018-0735-2

27. Sui YJ, Sun MY, Wu F, Yang LF, Di WH, Zhang GZ, et al. Inhibition of TMEM16A Expression Suppresses Growth and Invasion in Human Colonrectal Cancer Cells. PloS One (2014) 9:e15543. doi: 10.1371/journal.pone.015543

28. Guo et al. Ano1 Tumor-Promoting Mechanism

Frontiers in Oncology | www.frontiersin.org June 2022 | Volume 12 | Article 922838
48. Cornejo PP, Gokhale A, Duran C, Cui YY, Xiao QH, Hartzell HC. Anocortin 1 (TMEM16A) Ca2+-Activated Chloride Channel Stoichiometrically Interacts With an Ezrin-Radixin-Moesin Network. Proc Natl Acad Sci U.S.A. (2012) 109:10376–81. doi: 10.1073/pnas.120171899.

49. Seo Y, Jeong SW, Woo JH, Kwon OB, Lee S, Oh HL, et al. Diethylstilbestrol, a Novel ANO1 Inhibitor, Exerts an Anticancer Effect on Non-Small Cell Lung Cancer via Inhibition of ANO1. Int J Mol Sci (2021) 22:7100. doi: 10.3390/ijms22137100.

50. Yan YF, Ding XY, Han CH, Gao JJ, Liu ZT, Liu YN, et al. Involvement of ANO1 in the Development of Human Colorectal Cancer Cells. Oncotarget (2016) 7:78619–30. doi: 10.18632/oncotarget.12524

51. Bar A, Gutierrez T, Kulkarni S, Kemp C, Bonenfant D, Voshol H, et al. ANO1/TMEM16A Interacts With EGFR and Correlates With Sensitivity to EGFR-Targeting Therapy in Head and Neck Cancer. Oncotarget (2015) 6:9173–88. doi: 10.18632/oncotarget.3277.

52. Navas C, Porras IH, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF Receptor Signaling is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell (2012) 22:318–30. doi: 10.1016/j.ccr.2012.07.024.

53. Ardito CM, Gruner BM, Takeuchi MK, Martellato CL, Teichmann N, Mazur PK, et al. EGFR Receptor is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer Cell (2012) 22:304–17. doi: 10.1016/j.ccr.2012.07.024.

54. Betto G, Cherian OL, Piifferi S, Cenedese V, Boccaccio A, Menini A. Interactions Between Permeation and Gating in the TMEM16B/anoctamin2 Calcium-Activated Chloride Channel. J Gen Physiol (2014) 143:703–18. doi: 10.1085/jgp.201411182.

55. Ferrera L, Capato A, Ubbi J, Bussani E, Moran OZ, Ravazzolo R, et al. Regulation of TMEM16A Chloride Channel Properties by Alternative Splicing. J Biol Chem (2009) 284:33360–8. doi: 10.1074/jbc.M109.046607.

56. Zhang X, Zhang GH, Zhao ZI, Xiu RL, Jia J, Chen PP, et al. Cephatharine, a Novel Selective ANO1 Inhibitor With Potential for Lung Adenocarcinoma Therapy. Biochem Biophys Acta Mol Cell Res (2021) 1868:119132. doi: 10.1016/j.bbamem.2021.119132.

57. Vite JAC, Rangel SC, Jesús-Pérez JD, Figueroa IAA, Menchaca AAR, Cornejo PP, et al. Revealing the Activation Pathway for TMEM16A Chloride Channels From Macroscopic Currents and Kinetic Models. Pflugers Arch (2016) 469:24–57. doi: 10.1007/s00424-016-1830-9.

58. Carpenter G. The EGFR Receptor: A Nexus for Trafficking and Signaling. Bioessays (2020) 22:697–707. doi: 10.1002/bies.20178. doi: 10.1002/bies.20178. doi: 10.1002/bies.20178.

59. Hodeif Y, Yu F, Courjaret R, Nader N, Dib M, Sun L, et al. Regulation and Role of Store-Operated Ca2+ Entry in Cellular Proliferation. Eur J Med Chem (2017) 297:101016. doi: 10.1016/j.ejmech.2017.01.002.

60. Shi S, Ma B, Sun F, Qu C, An HL. Theaflavin Binds to a Druggable Pocket of TMEM16A Channel and Inhibits Lung Adenocarcinoma Cell Viability. J Biol Chem (2021) 297:101016. doi: 10.1016/j.jbc.2021.10.

61. Filippou A, Pehkonen H, Karhemo PR, Viinänen J, Nieminen AI, Klefström H, et al. ANO1 Expression Orchestrates P27kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) (2021) 13:1170. doi: 10.3390/cancers13051170.

62. Lippitz BE. Cytotokie Patterns in Patients With Cancer: A Systematic Review. Lancet Oncol (2013) 14:e218–28. doi: 10.1016/S1470-4255(12)70582-X.

63. Seo Y, Kim J, Chang J, Kim SS, Namkung W. Kim L. Synthesis and Biological Evaluation of Novel An9 Derivatives as Potent and Selective ANO1 Inhibitors. Eur J Med Chem (2018) 160:245–55. doi: 10.1016/j.ejmech.2018.10.002.

64. Jo S, Yang E, Lee Y, Jeon D, Namkung W. Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells Through Downregulation of ANO1. Int J Mol Sci (2021) 22:12037. doi: 10.3390/ijms22121037.

65. Seo Y, Ryu K, Park J, Jeon DK, Jo S, Lee HK, et al. Inhibition of ANO1 by Luteolin and its Cytotoxicity in Human Prostate Cancer PC-3 Cells. PLoS One (2017) 12:e0174935. doi: 10.1371/journal.pone.0174935.

66. Kim T, Cho S, Oh H, Hur J, Kim H, Choi YH, et al. Design of Anticancer 2,4-Diaminopyrimidines as Novel Anocortin 1 (ANO1) Ion Channel Blockers. Molecules (2020) 25:5180. doi: 10.3390/organisms25215180.

67. Wang L, Yu PW. miR-300 Promotes Proliferation and EMT-Mediated Colorectal Cancer Migration and Invasion by Targeting P35. Oncol Rep (2016) 36:3225–32. doi: 10.3892/or.2016.5193.

68. Liu MJ, He XS, Xiao XJ, Wang YC. Overexpression of miR-422a Inhibits Cell Proliferation and Invasion, and Enhances Chemosensitivity in Osteosarcoma Cells. Oncol Rep (2016) 36:3371–8. doi: 10.3892/or.2016.5182.

69. Yi CH, Zhou DM. MicroRNAs in Colorectal Cancer—From Pathogenesis to Therapy. J Exp Clin Cancer Res (2016) 35:43. doi: 10.1186/s13046-016-0340-6.

70. Godse NR, Khan N, Yochum AZ, Gomez CR, Kemp C, Shiwasaki DJ, et al. TMEM16A/ANO1 Inhibits Proliferation Via Downregulation of Bim Expression. Clin Cancer Res (2017) 23:7342–32. doi: 10.1158/1078-0432.CCR-17-1561.

71. Zhang AL, Yan XX, Li HL, Gu ZF, Zhang P, Zhang HL, et al. TMEM16A Protein Attenuates Lipopolysaccharide-Mediated Inflammatory Response of Human Lung Epithelial Cell Line A549. Exp Lung Res (2014) 40:237–50. doi: 10.3109/03013970.2014.905655.

72. Fribom R, Sellberg F, Xu C, Zhao A, Larsson C, Lui WO, et al. Biochemical Inhibition of DOG1/TMEM16A Achieves Antitumoral Effects in Human Gastrointestinal Stromal Tumor Cells. In Vitro. Anticancer Res (2019) 39:3433–42. doi: 10.21873/anticancer.13489.

73. Filippou A, Pehkonen H, Karhemo PR, Viinänen J, Nieminen AI, Klefström H, et al. ANO1 Expression Orchestrates P27kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma. Cancers (Basel) (2021) 13:1170. doi: 10.3390/cancers13051170.

74. Peretti M, Angelini M, Savalli N, Florio T, Yuspa SH, Mazzanti M. Chloride Channels in Cancer: Focus on Chloride Intracellular Channel 1 and 4 (CLIC1 AND CLIC4) Proteins in Tumor Development and as Novel Therapeutic Targets. Biochem Biophys Acta (2015) 1843:2523–31. doi: 10.1016/j.bbamem.2014.12.012.

75. Wang H, Zou L, Ma K, Yu JK, Wu HZ, Wei MJ, et al. Cell-Specific Mechanisms of TMEM16A Ca(2+)-Activated Chloride Channel in Cancer. Mol Cancer (2017) 16:152. doi: 10.1186/s12943-017-0720-x.
Their Anticancer Effects. *Pharmacol Res* (2020) 156:104763. doi: 10.1016/j.phrs.2020.104763

87. Bartel DP. Micronase: Genomics, Biogenesis, Mechanism, and Function. *Cell* (2004) 116:281–97. doi: 10.1016/s0092-8674(04)00045-5

88. Chen L, Luo L, Chen W, XuHX, Chen F, Chen LZ, et al. MicroRNA-24 Increases Hepatocellular Carcinoma Cell Metastasis and Invasion by Targeting P53: miR-24 Targeted P53. *BioMed Pharmacother* (2016) 84:1113–8. doi: 10.1016/j.biopha.2016.10.051

89. Wang YF, Liu LL, Liu XQ, Zhang H, Liu JM, Feng B, et al. Shugoshin1 Enhances Multidrug Resistance of Gastric Cancer Cells by Regulating MRP1, Bcl-2, and Bax Genes. *Tumor Biol* (2013) 34:2205–14. doi: 10.1007/s13277-013-0758-3

90. Feng H, Wang YL, Su JJ, Liang HW, Zhang CY, Chen X, et al. MicroRNA-148a Suppresses the Proliferation and Migration of Pancreatic Cancer Cells by Down-Regulating ErbB3. *Pancreas* (2016) 45:1263–71. doi: 10.1097/MPA.0000000000000677

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Guo, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.